Evidence map›Paper›PMID 34521767›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.

Regina Andrijes, Rahul K Hejmadi, Matthew Pugh, Sundaresan Rajesh, Vera Novitskaya, Maha Ibrahim, Michael Overduin, Chris Tselepis, Gary W Middleton, Balázs Győrffy and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Integrating computational engines to identifyFrontiers in immunology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Regina AndrijesInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0002-9953-4787
Rahul K HejmadiUniversity Hospitals Birmingham National Health Service Foundation Trust, Birmingham B15 2TH, United Kingdom.
Matthew PughInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0002-6324-661X
Sundaresan RajeshInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0003-3114-5141
Vera NovitskayaInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0002-6520-4317
Maha IbrahimInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.
Michael OverduinInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0002-3114-6585
Chris TselepisInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.
Gary W MiddletonInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.
Balázs GyőrffyDepartment of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary.
Andrew D BeggsInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0003-0784-2967
Fedor BerditchevskiInstitute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom; f.berditchevski@bham.ac.uk.
University of Birmingham · GBNational Health Service · GBSemmelweis University · HU

Funding

Cancer Research UK C1210/A4850Cancer Research UK C31641/A23923Medical Research Council 1575158Medical Research Council MR/M016587/1Medical Research Council MR/T001755/1
6 · The paper itself

Abstract

Early stages of colorectal cancer (CRC) development are characterized by a complex rewiring of transcriptional networks resulting in changes in the expression of multiple genes. Here, we demonstrate that the deletion of a poorly studied tetraspanin protein Tspan6 in Apc

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntineoplastic Agents, ImmunologicalApoptosisBiomarkers, TumorCell ProliferationCetuximabColorectal NeoplasmsErbB ReceptorsHumansMiceMice, Inbred C57BLMice, KnockoutPrognosisSurvival RateTetraspaninsAntineoplastic Agents, ImmunologicalBiomarkers, TumorCetuximabEGFR protein, humanErbB Receptorstetraspanin 6 protein, mouseTetraspaninsTSPAN6 protein, humanAPCmincolorectal cancerEGFRtetraspaninTGF alpha

Identifiers

PMID34521767
PMCPMC8488650
OpenAlexW3199802263

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.